June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Ex-vivo corneal permeation of nepafenac 0.1% ophthalmic suspension in different species (porcine, canine, equine and feline)
Author Affiliations & Notes
  • Roxanne Marie Rodriguez Galarza
    Clinical Sciences, Auburn University, Auburn, Alabama, United States
  • Haley Porter
    Harrison School of Pharmacy, Auburn University, Auburn, Alabama, United States
  • Jayachandra Ramapuram
    Harrison School of Pharmacy, Auburn University, Auburn, Alabama, United States
  • Sue Duran
    Clinical Sciences, Auburn University, Auburn, Alabama, United States
  • Eva Abarca
    Vetsuisse-Fakultät, University of Bern, Bern, Switzerland
    Clinical Sciences, Auburn University, Auburn, Alabama, United States
  • Footnotes
    Commercial Relationships   Roxanne Rodriguez Galarza, None; Haley Porter, None; Jayachandra Ramapuram, None; Sue Duran, None; Eva Abarca, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1080. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Roxanne Marie Rodriguez Galarza, Haley Porter, Jayachandra Ramapuram, Sue Duran, Eva Abarca; Ex-vivo corneal permeation of nepafenac 0.1% ophthalmic suspension in different species (porcine, canine, equine and feline)
      . Invest. Ophthalmol. Vis. Sci. 2017;58(8):1080.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Nepafenac, the only prodrug NSAID, has not been evaluated for use in dogs, cats or horses. The purpose of this investigation was to evaluate the ex-vivo transcorneal permeation of nepafenac 0.1% and compare its permeability profile across the porcine, canine, equine and feline corneas.

Methods : Fresh corneas were obtained from porcine, equine, canine and feline eyes free from corneal disease that were euthanized for reasons unrelated to this study. Corneal buttons (8 mm) were dissected using standard eye bank technique within 2 hours of enucleation. Corneas were mounted horizontally between the donor and the receiving compartments of an all-glass modified Franz diffusion cell (0.20cm2), which were maintained at 37°C. The donor compartment was filled with 0.1 mL of nepafenac 0.1% formulation (Nevanac, Alcon Laboratories, Inc Fort Worth, Texas, USA) n=4 per species studied. Samples (1ml phosphate buffered saline pH 7.4) were removed from the receiving compartment at set times: 0, 1, 2, 4, 6, 8, 12, 24 hours. High-performance liquid chromatography was used for nepafenac analysis concentration. The cornea and residual solutions were collected at the end of the experiment. Permeability parameters were determined and compared with ANOVA statistical analysis (P<0.05).

Results : Mean permeation rates (μg/cm2/hr ± SEM) were 0.752 ± 0.116, 1.281 ± 0.247, 0.944 ± 0.098 and 2.494 ±0.171 for the porcine, canine, equine and feline corneas, respectively. Permeation rate of nepafenac 0.1% of feline corneas was significantly greater than other species (p<0.05).

Conclusions : The results showed that 0.1% Nepafenac is able to permeate the cornea in normal porcine, canine, feline and equine eyes in an ex-vivo model. The data obtained demonstrated an interspecies difference with the feline cornea showing a significant increase in the permeation rate which suggests a potential alternative to treat intraocular inflammation in this species.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×